September 10, 2014 by Brad Perriello
Japanese regulators are the latest to probe the pending merger of Biomet and Zimmer to make sure it meets anti-trust muster.
Japanese anti-trust regulators are the latest to scrutinize the pending merger of Zimmer (NYSE:ZMH) and Biomet, joining agencies in the U.S. and Europe that are already looking at the deal.
The Japan Fair Trade Commission said Sept. 3 that it’s opening an investigation into the $13.35 billion mega-deal between the orthopedic device giants, 1st announced in April.
“With the knowledge that a more in-depth review is necessary, today, the JFTC requested Zimmer, etc. to submit further reports, information or materials,” the Japanese agency said in a press release. “The JFTC also starts seeking comments from 3rd parties concerning possible impacts on competition that would arise through the proposed integration.”
